PROTEOMICS

这个共享资源的目标是为研究人员提供具有成本效益的最先进的仪器，以及用于蛋白质组分析的专业知识，目的是识别用于预防，诊断和治疗癌症的新型蛋白质生物标志物。由于蛋白质通过翻译后修饰（PTM）、分泌和RNA剪接的极其多样的性质，加上其广泛的动态表达范围，因此不存在用于全局蛋白质表达的差异分析的单一平台。因此，这种共享资源结合并整合了几个不同的教师共同主任的仪器和专业知识，由院长P博士指导的一个组织单位。通过该机构和丹L.邓肯癌症中心的170万美元的设备，新员工的启动工资和运营支持，蛋白质组学共享资源（PSR）已经扩大了其技术能力和服务，并已大幅增长，成为癌症中心最重要的利用资源之一。PSR目前由四名联合主任（秦军博士、Richard Cook博士、黄世霞博士、梁东木博士）和六名训练有素的技术人员组成。自2006年CCSG提交以来开发的新技术和服务包括非质谱分析的蛋白质分析平台，如Luminex荧光珠系统、二维液体和凝胶电泳以及抗体/肽阵列;从细胞中分离的内源性蛋白质复合物的质谱鉴定和PTM分析，通过SILAC（在细胞中用重氨基酸进行稳定同位素标记）进行定量质谱蛋白质谱分析，并提高蛋白质的通量生产。 单克隆抗体（MAb）。这些新技术和服务，加上先前建立的蛋白质化学、蛋白质的MALDI-TOF鉴定和PTM分析、重组蛋白的杆状病毒表达和常规杂交瘤/单克隆抗体生产技术，创造了一个高度综合的蛋白质组学共享资源，能够通过定制抗体生产促进蛋白质生物标志物发现研究和翻译验证研究。我们将继续扩大和满足癌症中心的需求，通过共享仪器补助金申请，并提供专业知识和新的前沿蛋白质组学技术，因为该领域的迅速发展。

The goal of this shared resource is to provide investigators with cost effective state-of-the-art instrumentation, and specialized expertise for analysis of proteomes with the goal of identifying novel protein biomarkers with applications for prevention, diagnosis and treatment of cancer. Because of the extremely diverse nature of proteins through post-translation modifications (PTMs), secretion, and RNA splicing coupled with their wide dynamic range of expression, no single platform exists for differential analysis of global protein expression. This Shared Resource therefore combines and integrates the instrumentation and expertise of several different faculty co-directors under a single organizational unit directed by Dr. Dean P. Edwards. Through a combined investment by the Institution and the Dan L. Duncan Cancer Center of $1.7M in equipment, start-up salary for new staff and operational support, the Proteomics Shared Resource (PSR) has expanded its technological capabilities and services and has grown tremendously to become one of the heaviest utilized Resources of the Cancer Center. The PSR is currently staffed by four co-directors (Drs Jun Qin, Richard Cook, Shixia Huang, Eastwood Leung) and six highly trained technical staff. New technologies and services developed since the CCSG submission in 2006 include non-mass spectrometry-based protein profiling platforms such as the Luminex fluorescence bead system, two dimensional liquid and gel electrophoresis and antibody/peptide arrays; mass spectrometry identification and PTM analysis of endogenous protein complexes isolated from cells, quantitative mass spectrometry protein profiling by SILAC (stable isotope labeling with heavy amino acids in cells) and enhanced throughput production of monoclonal antibodies (MAbs). These new technologies and services, together with the previously established technologies of protein chemistry, MALDI-TOF identification and PTM analysis of proteins, baculovirus expression of recombinant proteins and conventional hybridoma/MAb production, have created a highly comprehensive Proteomic Shared Resource capable of facilitating both protein biomarker discovery research and translational validation studies through custom antibody production. We will continue to expand and meet the needs of the Cancer Center through shared instrument grant applications and by providing expertise and new leading edge proteomic technologies as the field rapidly evolves.